Mount Sinai and Rumi Scientific join hands to initiate autism drug discovery pipeline

The Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai and Rumi Scientific announced today that they will team up to initiate a drug discovery pipeline for rare genetic disorders that carry a high risk of autism. The project will initially involve the development and use of a platform that mimics the development of brain tissues, at high speed, allowing researchers to gain insights into how cells respond to three known genes implicated in autism.

Over the past several years, more than 100 genes have been identified that confer very high risk to autism when mutated, and the Seaver Center at Mount Sinai is one of the lead sites for these autism gene discoveries. We are eager to work together with Rumi Scientific, using their outstanding proprietary technology, to build a drug discovery pipeline for these monogenic causes of autism, with the ultimate goal of identifying lead therapeutic candidates that can be evaluated clinically."

Joseph D. Buxbaum, PhD, Director, Seaver Autism Center for Research and Treatment at Mount Sinai and Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai

Rumi Scientific's cutting-edge phenotypic platform mimics the development of human brain tissues, at high speed, using a proprietary technique to create highly reproducible organoids--tiny, self-organized tissue cultures that are derived from induced pluripotent stem cells (iPSCs), which can be crafted to replicate an organ or to express selected aspects like genetic mutations. The Rumi system incorporates sensitive machine-learning algorithms, helping to very precisely identify effects on a cell, thus predicting the therapeutic effect a drug could have on a human's diseased brain tissues. This advanced technology allows for an unprecedented ability to identify and quantify differences between diseased and healthy cells. Uniquely, Rumi's organoids focus on early development phenotypic signatures (how the gene mutation leads to disease), and since a large portion of autism genes are active even early in development, these tissue cultures present interesting possibilities for drug screening.

Initially, Mount Sinai's Seaver Center will provide iPSCs for three autism genes--ADNP, DDX3X, and FOXP1--and Rumi Scientific will probe the existence of phenotypic signatures associated with these genetic mutations using its proprietary organoid technology. The aim of creating a model platform for each of the three genes of interest is to allow translation of these proof-of-concept experiments into a robust high-throughput screening platform across which thousands of therapeutic compounds can be efficiently tested.

"We are very excited to be working with the world-class team at the Seaver Autism Center on their visionary approach to finding cures for autism. To date, no one has evaluated how specific autism mutations affect neural organization in a human context and at the level of a tissue; this collaboration creates the opportunity to discover robust phenotypic signatures which in turn could lead to valuable therapeutic possibilities" said Ilona Nemeth, Chief Executive Officer of Rumi Scientific.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Single-cell screening of cerebral organoids to identify developmental defects in autism